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Abstract Argyrophilic grain disease (AgD) is a four-re-
peat tauopathy that is almost exclusively restricted to allo-
cortical areas. Progressive supranuclear palsy and cortico-
basal degeneration also show predominant deposition of
four-repeat tau filaments, and are associated with the tau
H1 haplotype. We investigated a possible association be-
tween AgD and the tau H1 haplotype. In AgD, no differ-
ence between the prevalence of the tau H1 haplotype or
H1/H1 genotype was observed when compared to non-de-
mented control cases. These data suggest that a dysfunc-
tion of the tau protein in AgD – in contrast to other four-
repeat tauopathies – may arise irrespective of the genetic
background regarding the tau H1 or H2 haplotypes.
Keywords Argyrophilic grain disease · Four-repeat
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Introduction
Argyrophilic grain disease (AgD), first described by Braak
and Braak [2, 3] is a sporadic late onset dementia that ac-
counts for approximately 5% of all cases of dementia [5,
13, 17]. Among the oldest-old a recent study suggests that
AgD is the second most common cause of degenerative
dementia in Japan, after Alzheimer’s disease (AD) [12].
Morphologically, AgD is characterized by the presence of
neuronal argyrophilic grains (ArGs) in various limbic struc-
tures, including the hippocampus, the entorhinal cortex,
and the amygdala, and by coiled bodies in oligodendro-
cytes [2, 3]. Both filamentous lesions consist of the mi-
crotubule-associated protein tau in an abnormally hyper-
phosphorylated state [16]. Recent biochemical studies fur-
ther revealed that tau filamentous inclusions in AgD con-
sist primarily of tau isoforms with four microtubule-bind-
ing repeats (4R-tau) [14, 12, 19].
The predominant deposition of 4R-tau is also a feature
of progressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD) [7], and both tauopathies have been
shown to be associated with the tau H1 haplotype [1, 6].
A recent study also suggests a trend towards an increased
tau H1 haplotype in AgD. However, no statistically signif-
icant difference was found between AgD and non-tauopa-
thy controls [14]. Based on these findings, we investi-
gated the tau H1 haplotype in AgD, and wanted to know
whether the 4R tauopathies share a common pathogenic
mechanism causing dysfunction of the tau protein. Tau
haplotypes H1 and H2 were analyzed in a sample of 79 sub-
jects with neuropathologically confirmed AgD according
to published criteria [5, 13, 17], and in a sample of 148 non-
demented control subjects without ArGs.
Material and methods
AgD cases (n=79) diagnosed at the Department of Neuropathology,
Basel University, Switzerland were included in the present study.
There were 33 males, 46 females, with a median age of 85.9 years
(66–96 years). Standard neuropathological examination was per-
formed including the Gallyas silver technique, and immunohisto-
chemistry using antibodies against tau (AT8; 1:1,000; Innogenet-
ics, Gent, Belgium), β-amyloid (1:50; Dako, Glostrup, Denmark),
α-synuclein (1:2,000; Zymed, San Francisco, CA) and αB-crys-
tallin (1:1,000; Novocastra, Newcastle, UK). As controls, 148 non-
demented subjects were randomly selected from the Basel Inter-
Disciplinary study on Aging (IDA), Switzerland [10]. For molecu-
lar analysis, paraffin-embedded tissue samples and/or blood sam-
ples from the AgD cases and blood samples from the controls were
used.
Genomic DNA was extracted from tissue samples using DNeasy
tissue kits from Qiagen (Hilden, Germany), and from nucleated
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blood cells by the salting out method with modifications as de-
scribed [8], or using the QIAmp DNA blood kit. Taq DNA poly-
merase and deoxyribonucleotides were from Applied Biosystems
(Norwalk, CT). Oligonucleotides were synthesized by Microsynth
Inc. (Balgach, Switzerland); Spreadex EL 300 Wide-Mini S-100 gels
were from Elchrom Inc. (Cham, Switzerland). To characterize the
238-bp deletion in intron 9, which corresponds to the H2 haplotype
of the tau gene, the part of intron 9 containing the 238-bp deletion
was amplified using primers as previously described [1]. The am-
plicon was separated on a 2% agarose gel, dissolved, purified, and
subjected to dideoxy sequencing. The presence of the intronic dele-
tion was determined by allele-specific PCR. To investigate the pres-
ence of the deletion in each sample, the allele-specific antisense
primer tau-del9.asR, 5´-ATGGGTCTCCCACGACTGCATT-3´
(primer B), complimentary to parts of the intron sequence of the
deletion, was designed. Using all three primers [tau-del9F (A), tau-
del19.asR (B), and tau-del19.R (C)] in the same reaction combined
(multiplex PCR) or pairs of primers (A/B and A/C), the presence
of the deletion could be determined for both alleles of the individ-
ual investigated. Using the primer combination A/C, a fragment of
484 bp was obtained if the deletion was absent and a fragment of
246 bp if the intronic sequence was deleted. However, as the prob-
ability of amplifying a fragment of 484 bp is theoretically lower
than the probability of amplifying a fragment of 246 bp, we also
used the primer combination A/B. This PCR results in a fragment
of 187 bp if the intronic fragment is not deleted (Fig. 1A). For
group comparison, the Chi-square statistic was used.
Results
Histologically, all AgD cases were characterized by the
presence of abundant ArGs in limbic areas, including sec-
tor CA1 of the hippocampus, the entorhinal cortex and the
amygdala. Coiled bodies were mainly found in the white
matter underneath cortical regions rich in ArGs. AT8 re-
vealed various numbers of pretangle neurons in all AgD
cases as previously described [16]. In all cases, αB-crys-
tallin-stained ballooned neurons were predominantly found
in the amygdala, corroborating earlier results [15]. Asso-
ciated neurofibrillary tangles of the AD type were found in
a density and distribution corresponding to early transento-
rhinal or limbic Braak stages [Braak stage I, 17 (21.5%)
cases; Braak stage II, 45 (57.0%) cases; Braak stage III,
17 (21.5%) cases] [4]. Some diffuse Aβ deposits were
present in 40 (50.6%) cases, while the remaining cases were
totally devoid of senile plaques. In three cases there were
additional Lewy bodies and Lewy neurites. Vascular le-
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Fig. 1 A Length of the DNA sequence amplified by the primers
A, B, and C in the case of the presence or absence of the intronic
deletion of 238 bp. B Sequence alignment of the two DNA se-
quences (presence and absence of the intronic 238 bp sequence)
sions (e.g., small lacunar infarcts and/or cribriform state
of the basal ganglia) were found in 19 (24.1%) cases. All
AgD cases were devoid of concomitant PSP and CBD pa-
thology. The neuropathological findings of 24 cases have
been reported in earlier studies [17]. According to the
clinical records, 61 (77.2%) subjects with ArGs were re-
ported to be demented.
Figure 1B presents the sequence containing the 238-bp
deletion as well as the localization of the deletion itself.
Molecular analysis revealed the following tau genotype
frequencies for the AgD cases: genotype H1/H1 46 pa-
tients (58.2%), genotype H1/H2 30 patients (38.0%), and
genotype H2/H2 3 patients (3.8%). The tau genotype fre-
quencies of the non-demented control group did not differ
significantly from that of the AgD cases (P=0.672). Hence,
among the AgD cases, the H1 allele was found in 77.2%
and the H2 allele in 22.8%, respectively. These values did
not differ significantly from those obtained in the non-de-
mented control group (P=0.964) (Table 1).
Discussion
PSP and CBD are sporadic extrapyramidal syndromes
characterized by predominant 4R tau deposition, and both
have been shown to be associated with the tau H1 haplotype
[1, 6]. The sporadic late-onset dementia AgD has recently
been recognized as a 4R tauopathy [14, 18, 19]. Prelimi-
nary data based on a limited number of cases opened the
possibility that the tau H1 haplotype might also be over-
represented in AgD [14]. To test the hypothesis whether
the association of the tau H1 haplotype represents a com-
mon feature among 4R tauopathies, we analyzed the tau
haplotype in a cohort of 79 autopsy-confirmed AgD cases.
In contrast to PSP and CBD [1, 6], no difference was found
between the prevalence of the tau H1 haplotype or the
H1/H1 genotype in subjects with AgD when compared to
non-demented control cases.
The tau haplotype frequencies may vary when they are
studied in different populations. The tau H1/H1 genotype
is known to be very low in Norway (50%), while it is very
high in Japan (>95%). In our study, both the AgD and the
control cohorts are derived from the same urban-suburban
area in a northwestern region of Switzerland. In the control
cohort the frequencies of the tau H1 haplotype (77.0%)
and H1/H1 genotype (60.1%) are quite comparable with
values reported in different US- and UK-based popula-
tions [1, 6, 9, 14].
The present study suggests that there is no obligatory
association between the tau H1 haplotype and the 4R tauo-
pathies. Thus, the presence of the tau H1 haplotype seems
not to be a prerequisite for the type of filamentous tau pro-
tein deposited in 4R tauopathies. No association between
the tau H1 or H2 haplotype has been found in Pick’s dis-
ease [9, 11], a tauopathy characterized by the predominant
deposition of 3R tau filaments.
PSP, CBD and AgD share pathological and biochemi-
cal similarities with regard to an abnormal tau deposition.
In all these disorders, predominantly 4R tau filamentous
inclusions are found in neurons, astrocytes and oligoden-
drocytes. A recent study further demonstrates a high preva-
lence of ArGs in PSP and CBD cases [14]. In contrast, a
high prevalence of PSP and CBD cases has not been ob-
served in AgD cases, even in large cohorts of cases [5, 17].
Other differences, however, may confirm the separation
of PSP and CBD from AgD as distinct clinicopathological
entities. Clinically, PSP patients present with postural in-
stability, supranuclear vertical gaze palsy, parkinsonism,
pseudobulbar palsy and subcortical dementia. CBD pa-
tients also exhibit motor symptoms, parkinsonism and eye
movement abnormalities, and dementia has been reported
as their presenting syndrome in the majority of CBD pa-
tients. In contrast, although the clinical characteristics of
AgD remain to be fully established, motor symptoms and
parkinsonism are not characteristic features of AgD. Re-
cent studies rather suggest that AgD patients present with
dementia, and that personality changes and emotional im-
balances may precede memory failure [17]. The different
clinical presentation among 4R tauopathies is a function
of the anatomical distribution of their pathology. Thus,
PSP and CBD are characterized by a widespread tau pa-
thology in various cortical and subcortical structures, in-
cluding brain stem, while tau filamentous lesions in AgD
are almost exclusively restricted to allocortical areas.
Whether the tau haplotypes may affect the different topol-
ogy of neurodegeneration among 4R tauopathies remains
to be elucidated.
In conclusion, the present study further establishes AgD
as a rather distinct pathological entity within the heteroge-
neous group of tauopathies. Hence, the clinicopathologi-
cal differences between the 4R tauopathies PSP and CBD
on one hand and AgD on the other might be explained by
genetic or non-genetic differences that are involved in the
development of the tau protein dysfunction.
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Table 1 Tau haplotype and genotype frequency in neuropatho-
logically confirmed cases of argyrophilic grain disease and healthy
control subjects
Argyrophilic grain disease Control subjects
n=79 (cases) n=148 (cases)
Alleles
H1 122 (77.2%) 228 (77.0%)
H2 36 (22.8%) 68 (23.0%)
Genotypes
H1/H1 46 (58.2%) 89 (60.1%)
H1/H2 30 (38.0%) 50 (33.8%)
H2/H2 3 (3.8%) 89 (6.1%)
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